Home › Kidney Cancer › NCT02346435

The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry

Who can join

Ages 18 to 100 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
* Age ≥ 18 and able to read, understand and sign informed consent.
* Must be willing to adhere to the treatment algorithm and time constraints therein.

Exclusion Criteria:

* Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.

About the study

Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.

Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 600 · Started: 2009-01

Contact the study team

• Nirmish Singla · Phone: 410-502-3692

Official record on ClinicalTrials.gov — NCT02346435

Locations in the U.S.

Conditions

• Kidney Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.